Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
4.
J Cardiovasc Echogr ; 27(1): 1-6, 2017.
Article in English | MEDLINE | ID: mdl-28465981

ABSTRACT

CONTEXT: Heart failure with preserved ejection fraction (HFpEF) is a clinical syndrome associated with diastolic function abnormalities. It remains unclear which factors, if any, can predict the transition from asymptomatic diastolic dysfunction to an overt symptomatic phase. MATERIALS AND METHODS: Patients hospitalized with suspected heart failure between January 2012 and November 2014 with a transthoracic echocardiogram demonstrating preserved systolic function were screened (n = 425). Patients meeting the American College of Cardiology Foundation/American Heart Association definition for HFpEF (n = 40) were matched in a 1:1 fashion to individuals admitted for hypertensive urgency with diastolic dysfunction and neither pulmonary edema nor history of heart failure (n = 40). The clinical records and echocardiograms of all eighty patients included in this retrospective study were reviewed. RESULTS: Patients with HFpEF had higher body mass index (BMI), creatinine, beta-blocker use, and Grade 2 diastolic dysfunction when compared to the hypertensive control population. Echocardiographic analysis demonstrated higher right ventricular systolic pressures, left ventricular mass index, E/A, and E/e' in patients with HFpEF. Similarly, differences were observed in most left atrial (LA) parameters including larger LA maximum and minimum volume indices, as well as smaller LA-emptying fractions in the heart failure group. Multivariate logistic regression analysis revealed LA minimum volume index (odds ratio [OR]: 1.23 [1.09-1.38], P = 0.001) to have the strongest association with heart failure hospitalization after adjustment for creatinine (OR: 7.09 [1.43-35.07], P = 0.016) and BMI (OR: 1.11 [0.99-1.25], P = 0.074). CONCLUSION: LA minimum volume index best correlated with HFpEF in this patient cohort with diastolic dysfunction.

5.
J Am Coll Cardiol ; 69(13): 1694-1703, 2017 Apr 04.
Article in English | MEDLINE | ID: mdl-28359515

ABSTRACT

BACKGROUND: Current electrocardiographic (ECG) criteria for the diagnosis of left ventricular hypertrophy (LVH) have low sensitivity. OBJECTIVES: The goal of this study was to test a new method to improve the diagnostic performance of the electrocardiogram. METHODS: The study was divided into 2 groups, a test and a validation cohort. In the test cohort, 94 patients were analyzed, including 47 with the diagnosis of hypertensive crisis and 47 with normal blood pressure at admission. Echocardiography was used to estimate the left ventricular mass index. Area under the curve (AUC) analysis was used for comparison of single and combined leads. The McNemar test was used to assess agreement among the ECG criteria against the left ventricular mass index. The proposed ECG criteria involved measuring the amplitude of the deepest S wave (SD) in any single lead and adding it to the S wave amplitude of lead V4 (SV4). Currently accepted LVH ECG criteria such as Cornell voltage and Sokolow-Lyon were used for comparison. The validation cohort consisted of 122 consecutive patients referred for an echocardiogram regardless of the admitting diagnosis. RESULTS: The SD was the most accurate single lead measurement for the diagnosis of LVH (AUC: 0.80; p < 0.001). When both cohorts were analyzed, the SD + SV4 criteria outperformed Cornell voltage with a significantly higher sensitivity (62% [95% confidence interval [CI]: 50% to 72%] vs. 35% [95% CI: 24% to 46%]). The specificities of all the criteria were ≥90%, with no significant difference among them. CONCLUSIONS: The proposed criteria for the ECG diagnosis of LVH improved the sensitivity and overall accuracy of the test.


Subject(s)
Electrocardiography , Hypertrophy, Left Ventricular/diagnosis , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Humans , Male , Middle Aged
6.
Am Heart J ; 177: 153-9, 2016 07.
Article in English | MEDLINE | ID: mdl-27297861

ABSTRACT

OBJECTIVE: To compare the accuracy of R2CHADS2, CHADS2, and CHA2DS2-VASc scores vs the Society of Thoracic Surgeons (STS) score as predictors of morbidity and mortality after cardiovascular surgery. METHODS: All patients who underwent cardiothoracic surgery at our institution from January 2008 to July 2013 were analyzed. Only those patients who fulfilled the criteria for STS score calculation were included. The R2CHADS2 score was computed as follows: 2 points for GFR < 60 mL/min/1.73 m(2) (R2), prior stroke or TIA (S2); 1 point for history of congestive heart failure (C), hypertension (H), age ≥75 years (A), or diabetes (D). Area under the curve (AUC) analysis was used to estimate the accuracy of the different scores. The end point variables included operative mortality, permanent stroke, and renal failure as defined by the STS database system. RESULTS: Of the 3,492 patients screened, 2,263 met the inclusion criteria. These included 1,160 (51%) isolated valve surgery, 859 (38%) coronary artery bypass graft surgery, and 245 (11%) combined procedures. There were 147 postoperative events: 75 (3%) patients had postoperative renal failure, 48 (2%) had operative mortality, and 24 (1%) had permanent stroke. AUC analysis revealed that STS, R2CHADS2, CHADS2, and CHA2DS2-VASc reliably estimated all postoperative outcomes. STS and R2CHADS2 scores had the best accuracy overall, with no significant difference in AUC values between them. CONCLUSION: The R2CHADS2 score estimates postoperative events with acceptable accuracy and if further validated may be used as a simple preoperative risk tool calculator.


Subject(s)
Cardiac Surgical Procedures , Postoperative Complications/epidemiology , Age Factors , Aged , Aged, 80 and over , Area Under Curve , Diabetes Mellitus/epidemiology , Female , Glomerular Filtration Rate , Heart Failure/epidemiology , Humans , Hypertension/epidemiology , Ischemic Attack, Transient/epidemiology , Male , Middle Aged , Postoperative Complications/mortality , Renal Insufficiency/epidemiology , Risk Assessment , Risk Factors , Stroke/epidemiology
7.
Am J Cardiol ; 115(6): 758-62, 2015 Mar 15.
Article in English | MEDLINE | ID: mdl-25616533

ABSTRACT

Despite its association with cardioembolic stroke, atrial fibrillation (AF) appears to be inconsistent as a risk factor for postoperative strokes in patients who underwent cardiac surgery. Furthermore, the relation between AF and the CHA2DS2VASc score has not been definitively established with respect to postoperative stroke. We retrospectively analyzed the records of all cardiac surgery performed at our institution between January 2008 and July 2013. Baseline characteristics, operative data, and postoperative outcomes were compared in patients who developed stroke with those who did not. Previously recognized stroke risk factors, including AF, were analyzed along with the CHADS2 and CHA2DS2VASc scores. A total of 3,492 consecutive patients were identified, of which 2,077 (60%) underwent valve surgery, 915 (26%) had coronary artery bypass grafting, 399 (11%) underwent combined coronary artery bypass grafting and valve procedures, and 101 (3%) had other cardiac operations. Postoperative ischemic strokes occurred in 44 patients (1.2%). The development of a stroke was associated with older age (74 ± 12 vs 69 ± 12, p = 0.008), preoperative antiplatelet medication use (38.6% vs 24.5%, p = 0.043), congestive heart failure (37% vs 20%, p = 0.002), and greater CHADS2 (2.48 ± 1.3 vs 1.98 ± 1.1, p = 0.015) and CHA2DS2VASc scores (4.2 ± 1.8 vs 3.4 ± 1.6, p = 0.002). Multivariable analysis demonstrated that the CHA2DS2VASc score was the only independent predictor of postoperative strokes (odds ratio 1.25; 95% confidence interval 1.05 to 1.5, p = 0.014). In conclusion, the CHA2DS2VASc score appears to predict postoperative strokes independent of the presence of AF.


Subject(s)
Cardiac Surgical Procedures/adverse effects , Stroke/diagnosis , Aged , Aged, 80 and over , Atrial Fibrillation/complications , Coronary Artery Bypass/adverse effects , Female , Humans , Logistic Models , Male , Middle Aged , Predictive Value of Tests , Research Design , Retrospective Studies , Risk Assessment , Risk Factors , Sensitivity and Specificity , Severity of Illness Index , Stroke/etiology , Stroke/mortality , Stroke/therapy , Thrombolytic Therapy , Time Factors , Treatment Outcome
8.
Trends Cardiovasc Med ; 24(6): 232-40, 2014 Aug.
Article in English | MEDLINE | ID: mdl-25106084

ABSTRACT

Medical practitioners have treated atherosclerotic disease with chelation therapy for over 50 years. Lack of strong of evidence led conventional practitioners to abandon its use in the 1960s and 1970s. This relegated chelation therapy to complementary and alternative medicine practitioners, who reported good anecdotal results. Concurrently, the epidemiologic evidence linking xenobiotic metals with cardiovascular disease and mortality gradually accumulated, suggesting a plausible role for chelation therapy. On the basis of the continued use of chelation therapy without an evidence base, the National Institutes of Health released a Request for Applications for a definitive trial of chelation therapy. The Trial to Assess Chelation Therapy (TACT) was formulated as a 2 × 2 factorial randomized controlled trial of intravenous EDTA-based chelation vs. placebo and high-dose oral multivitamins and multiminerals vs. oral placebo. The composite primary endpoint was death, reinfarction, stroke, coronary revascularization, or hospitalization for angina. A total of 1708 post-MI patients who were 50 years or older with a creatinine of 2.0 or less were enrolled and received 55,222 infusions of disodium EDTA or placebo with a median follow-up of 55 months. Patients were on evidence-based post-MI medications including statins. EDTA proved to be safe. EDTA chelation therapy reduced cardiovascular events by 18%, with a 5-year number needed to treat (NNT) of 18. Prespecified subgroup analysis revealed a robust benefit in patients with diabetes mellitus with a 41% reduction in the primary endpoint (5-year NNT = 6.5), and a 43% 5-year relative risk reduction in all-cause mortality (5-year NNT = 12). The magnitude of benefit is such that it suggests urgency in replication and implementation, which could, due to the excellent safety record, occur simultaneously.


Subject(s)
Cardiovascular Agents/therapeutic use , Edetic Acid , Metals, Heavy , Vitamins/therapeutic use , Xenobiotics , Cardiovascular Diseases/drug therapy , Cardiovascular Diseases/etiology , Chelating Agents/administration & dosage , Chelating Agents/pharmacokinetics , Chelation Therapy/methods , Drug Therapy, Combination , Edetic Acid/administration & dosage , Edetic Acid/pharmacokinetics , Endpoint Determination , Evidence-Based Medicine , Female , Health Services Needs and Demand , Humans , Male , Metals, Heavy/adverse effects , Metals, Heavy/classification , Middle Aged , Outcome Assessment, Health Care , Randomized Controlled Trials as Topic , United States , Xenobiotics/adverse effects , Xenobiotics/classification
9.
Rev Cardiovasc Med ; 15(2): 189-95, 2014.
Article in English | MEDLINE | ID: mdl-25051137

ABSTRACT

Subclavian artery stenosis (SAS) is a significant form of peripheral artery disease, which may be a marker of diffuse atherosclerosis and increased risk for cardiovascular events. SAS can lead to symptomatic ischemia affecting the upper extremities, the brain, and, in some cases, the heart. In general, asymptomatic subclavian artery disease is treated with medical therapy and invasive treatment is reserved for the more symptomatic patients. This article discusses the evaluation of four patients with varying presentations of subclavian artery disease.


Subject(s)
Coronary-Subclavian Steal Syndrome , Subclavian Artery , Subclavian Steal Syndrome , Aged , Aged, 80 and over , Angioplasty/instrumentation , Constriction, Pathologic , Coronary-Subclavian Steal Syndrome/diagnosis , Coronary-Subclavian Steal Syndrome/physiopathology , Coronary-Subclavian Steal Syndrome/therapy , Female , Humans , Male , Predictive Value of Tests , Recurrence , Stents , Subclavian Artery/diagnostic imaging , Subclavian Artery/physiopathology , Subclavian Steal Syndrome/diagnosis , Subclavian Steal Syndrome/physiopathology , Subclavian Steal Syndrome/therapy , Tomography, X-Ray Computed , Treatment Outcome , Ultrasonography, Doppler, Color , Vascular Patency , Vascular Surgical Procedures
10.
J Cardiovasc Pharmacol Ther ; 19(3): 310-4, 2014 May.
Article in English | MEDLINE | ID: mdl-24367008

ABSTRACT

Contrast-induced nephropathy (CIN) is a significant cause of morbidity and mortality and effective strategies for its prevention are greatly needed. The purpose of this retrospective, single-center study was to investigate whether nitrate use during percutaneous coronary artery intervention reduces the incidence of CIN. Chart review of all individuals who underwent percutaneous coronary intervention (PCI) from April 2010 to March 2011 was done. Included in the study were patients who were admitted to the hospital after percutaneous coronary artery intervention and had baseline and follow-up creatinine measured. Patients with end-stage renal disease requiring dialysis and those patients with insufficient information to calculate Mehran score were excluded. There were 199 patients who met the eligibility criteria for inclusion in this study. In the identified population, postprocedure renal function was compared between 112 patients who received nitrates prior to coronary intervention and 87 who did not. Baseline characteristics were similar between the 2 groups. Contrast-induced nephropathy was defined as either a 25% or a 0.5 mg/dL, or greater, increase in serum creatinine during the first 48 to 72 hours after contrast exposure. Overall, 43 (21.6%) patients developed CIN post-PCI. Of the patients who received nitrates, 15.2% developed renal impairment when compared to 29.9% in those who did not (odds ratio [OR] = 0.42, 95% confidence interval [CI] 0.21-0.84, P = .014). Multivariate logistic regression analysis demonstrated that nitrate use was independently correlated with a reduction in the development of contrast nephropathy (OR = 0.334, 95% CI 0.157-0.709, P = .004). Additionally, of the various methods of nitrate administration, intravenous infusion was shown to be the most efficacious route in preventing renal impairment (OR = 0.42, 95% CI 0.20-0.90, P = .03). In conclusion, the use of nitrates prior to PCI, particularly intravenous nitroglycerin infusion, may be associated with a decreased incidence of CIN.


Subject(s)
Acute Kidney Injury/chemically induced , Acute Kidney Injury/prevention & control , Contrast Media/adverse effects , Nitrates/administration & dosage , Percutaneous Coronary Intervention/methods , Age Factors , Aged , Aged, 80 and over , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...